Matthijs Oudkerk, MD, Ph.D., được vinh danh với Giải thưởng Lãnh đạo Quốc tế James L. Mulshine, MD cho vai trò quan trọng trong việc đảm bảo sự chấp nhận toàn cầu đối với sàng lọc ung thư phổi

FHOẶC PHÁT HÀNH NGAY LẬP TỨC

Kyra Meister
703-836-1746
kyra.meister@preventcancer.org

Alexandria, Va. – Kicking off Lung Cancer Awareness Month, the Prevent Cancer Foundation will honor Professor Matthijs Oudkerk with the James L. Mulshine, M.D., International Leadership Award on Thursday, November 2 at the 20th annual Quantitative Imaging Workshop. The annual Mulshine Leadership Award is given to someone who has had a profound impact on reducing the toll of lung cancer, COPD and cardiovascular disease on the health of Americans and people around the world.

As a co-principal investigator of the NELSON randomized screening trial, Professor Oudkerk was influential in the global scaling of lung cancer screening. The NELSON trial successfully demonstrated the mortality benefit of lung cancer screening for people at high risk in Europe and led to 27 nations recognizing the value of lung cancer screening. These counties have a total population of 750 million people. Those eligible for lung cancer screening will be smokers or former smokers with significant tobacco-exposure (>20 pack years) after they reach age 50. As countries continue work to implement lung cancer screening for those at high risk across Europe, more cancers will be found at earlier, more treatable stages in addition to fewer numbers of people who die from the disease.

“The Foundation is honored to recognize Professor Oudkerk as we celebrate two decades of the Quantitative Imaging Workshop,” said Prevent Cancer Foundation Founder Carolyn “Bo” Aldigé. “What makes Professor Oudkerk’s accomplishments so exceptional is his unwavering commitment to implementing equitable lung cancer screening services not only across Europe, but around the world. His work has saved and will continue to save countless lives by helping people detect lung cancer early, which leads to better outcomes.”

Professor Oudkerk is currently professor and chair of radiology and the chief medical scientific director of the Center for Medical Imaging at the University Medical Center Groningen, Netherlands. He is also the founder and past president of the European Society of Cardiac Radiology and former chairman of radiology departments of DDHK Erasmus MC Rotterdam and University Medical Center Groningen. In 2019, he was ranked as one of the most influential researchers in radiology in Europe.

Past recipients of the award include:

• 2022 – Andrea B. McKee, M.D. and the late Brady J. McKee, M.D. for their contributions to ensuring community hospitals and cancer centers provide equitable access to the highest quality screenings and their instrumental involvement in developing the LungRADS system. 
• 2021 – Mary Pasquinelli, DNP, DNP, APRN, FNP-BC, Advanced Practice Nurse, Pulmonary and Medical Oncology, University of Illinois Hospital and Health Science System for her efforts to ensure that she and the team she leads were able to bring a new service to a community that represents a critical challenge from both a health and equity perspective.  
• 2020 – Daniel C. Sullivan, M.D. for his work in founding and chairing the Quantitative Imaging Biomarkers Alliance (QIBA). QIBA is committed to transforming patient care by making radiology a more quantitative science.  
• 2019 – Andrew C. von Eschenbach, M.D., Former Director, National Cancer Institute, for his design, implementation and management of the largest and most expensive clinical trial in its history, the National Lung Screening Trial (NLST).  
• 2018 – Sharon Y. Eubanks, U.S. Department of Justice, for her work as the lead Justice Department prosecutor in the landmark racketeering trial against Big Tobacco, a case which defied predictions and was won by the government.  
• 2017 – The late John Walsh, President and CEO of the COPD Foundation and President and Founder of the Alpha One Foundation.  
• 2016 – Laurie Fenton Ambrose, President and CEO of the Lung Cancer Alliance, for her efforts to guide patient advocacy groups in successful efforts to gain coverage of lung cancer screening by the Centers for Medicare & Medicaid Services (CMS).  
• 2015 – Claudia Henschke, Ph.D., M.D., Mt. Sinai Medical Center, as a pioneer of the use of low-dose spiral CT to screen for lung cancer.  
• 2014 – CVS Health, award accepted by Nancy Gagliano, M.D., CVS Chief Medical Officer, in recognition of the company’s bold decision to discontinue the sale of tobacco products in their stores. 
• 2013 (Inaugural year of the Award) – Cheryl G. Healton, Ph.D., President and CEO, Legacy Foundation and Dean of the College of Public Health at New York University, in recognition of over 25 years of tireless work in public health, specifically on tobacco control.

The 20th annual Quantitative Imaging Workshop will explore how to responsibly integrate the medical information available from annual chest CT screening to directly guide management of an eligible screening participant for three of the most lethal tobacco-related diseases with the goal to markedly improve overall health outcomes.

The Workshop will take place November 2-3 as a virtual event, with the award ceremony happening on November 2 at 10:30 am ET. For more information about the Quantitative Imaging Workshop and the award, visit the Prevent Cancer Foundation’s website. 

###

Giới thiệu về Quỹ phòng chống ung thư^®

Quỹ phòng chống ung thư^® là nước Mỹ duy nhất-dựa trên tổ chức phi lợi nhuận cô độc tận tụy ĐẾN bệnh ung thư phòng ngừa và sớm phát hiện. Thông qua nghiên cứu, giáo dục, tiếp cận cộng đồng và vận động, chúng tôi đã giúp vô số người tránh được chẩn đoán ung thư hoặc phát hiện ung thư của họ đủ sớm để được điều trị thành công. Chúng tôi được thúc đẩy bởi tầm nhìn về một thế giới nơi ung thư có thể phòng ngừa được, có thể phát hiện được và có thể đánh bại cho tất cả.

Tổ chức đang nỗ lực đáp ứng thách thức giảm 40% tử vong do ung thư vào năm 2035. Để đạt được điều này, chúng tôi là cam kết đầu tư $20 triệu cho các công nghệ tiên tiến nhằm phát hiện sớm và tiến triển ung thư đasàng lọc ung thư, $10 triệu để mở rộng khả năng tiếp cận sàng lọc và tiêm chủng ung thư về mặt y khoa các cộng đồng chưa được phục vụ đầy đủ và $10 triệu để giáo dục công chúng về các lựa chọn sàng lọc và tiêm chủng.

Để biết thêm thông tin, vui lòng truy cập www.preventcancer.org.